Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study

The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?

(2021) Matteo Piga et al.   Journal of Clinical Medicine

Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients

(2021) Martina Frodlund et al.   Frontiers in Medicine

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

(2020) Maximilian F Konig et al.   ANNALS OF THE RHEUMATIC DISEASES

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus

(2020) Ioannis Parodis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice

(2020) Ioannis Parodis et al.   Frontiers in Medicine

Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis

(2020) Sonali Narain et al.   CURRENT OPINION IN RHEUMATOLOGY

Does SLE widen or narrow race/ethnic disparities in the risk of five co-morbid conditions? Evidence from a community-based outpatient care system

(2019) T Falasinnu et al.   LUPUS

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

(2019) Sarah Reid et al.   ANNALS OF THE RHEUMATIC DISEASES

Longitudinal anti‐nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent‐onset disease

(2019) M. Frodlund et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience

(2019) A Segarra et al.   LUPUS

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE

(2019) Laura S van Dam et al.   RHEUMATOLOGY

Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab

(2018) Savino Sciascia et al.   ANNALS OF THE RHEUMATIC DISEASES

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors

(2018) Tobias Alexander et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination

(2018) Eckart Mummert et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus

(2018) Tomonori Ishii et al.   Modern Rheumatology

The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis

(2017) H Zhang et al.   LUPUS

Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases

(2017) C Sjöwall et al.   LUPUS

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

(2015) Tobias Alexander et al.   ANNALS OF THE RHEUMATIC DISEASES

Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus

(2015) Mathilda Björk et al.   BMC MUSCULOSKELETAL DISORDERS

Mechanisms of Autoantibody Production in Systemic Lupus Erythematosus

(2015) Shuhong Han et al.   Frontiers in Immunology

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

(2008) T. Alexander et al.   BLOOD

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE